ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

LPCN vs DARE // ALTMAN Z-SCORE & DEBT/EQUITY

Lipocine Inc. (NASDAQ) VS. Dare Bioscience Inc. (NASDAQ) • 15-METRIC TALLY: LPCN 0 — DARE 4
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (LPCN VS. DARE) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC LPCN DARE SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — 71.30% — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -35.00% 0.00 TIE /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield — — — TIE /fcf-yield <GO>
Operating Margin -60.00% -60.00% 0.00 TIE /operating-margins <GO>
Net Profit Margin -60.00% -60.00% 0.00 TIE /net-margins <GO>
Revenue Growth (YoY) -65.00% 180.00% -245.00 DARE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity ACTIVE — — — TIE /balance-sheet <GO>
Piotroski F-Score Quality 1/9 4/9 -3.00 DARE /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 37.7 39.6 -1.90 DARE /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $12.5M $13.4M -$873.2K DARE /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR LPCN REV DARE REV LPCN GROSS % DARE GROSS % LPCN FCF DARE FCF
FY 2025 $2.0M $1.0M — 71.3% -$9.8M -$10.3M
FY 2024 $11.2M $9.8K — 98.0% -$1.3M $4.9M
FY 2023 -$2.9M $2.8M — — -$11.9M -$38.9M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
LPCN // BETA —
DARE // BETA —